MX2010006019A - Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis. - Google Patents

Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.

Info

Publication number
MX2010006019A
MX2010006019A MX2010006019A MX2010006019A MX2010006019A MX 2010006019 A MX2010006019 A MX 2010006019A MX 2010006019 A MX2010006019 A MX 2010006019A MX 2010006019 A MX2010006019 A MX 2010006019A MX 2010006019 A MX2010006019 A MX 2010006019A
Authority
MX
Mexico
Prior art keywords
methods
delivering sirna
via iontophoresis
sirna via
iontophoresis
Prior art date
Application number
MX2010006019A
Other languages
English (en)
Inventor
William Schubert
Peyman Moslemy
Mike Patane
Phil Isom
Original Assignee
Eyegate Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharma S A S filed Critical Eyegate Pharma S A S
Publication of MX2010006019A publication Critical patent/MX2010006019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Se describen en la presente formulaciones de ARNsi adecuadas para la administración por iontoforesis ocular, dispositivos para la administración iontoforética de ARNsi y métodos de uso de las mismas.
MX2010006019A 2007-12-05 2008-12-05 Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis. MX2010006019A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US563507P 2007-12-05 2007-12-05
US4797208P 2008-04-25 2008-04-25
PCT/US2008/085709 WO2009076220A1 (en) 2007-12-05 2008-12-05 Methods for delivering sirna via iontophoresis

Publications (1)

Publication Number Publication Date
MX2010006019A true MX2010006019A (es) 2010-08-04

Family

ID=40449106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006019A MX2010006019A (es) 2007-12-05 2008-12-05 Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.

Country Status (10)

Country Link
US (1) US20110038937A1 (es)
EP (1) EP2231264A1 (es)
JP (1) JP2011505917A (es)
CN (1) CN101965212A (es)
AU (1) AU2008335346A1 (es)
BR (1) BRPI0820959A2 (es)
CA (1) CA2707964A1 (es)
IL (1) IL206090A0 (es)
MX (1) MX2010006019A (es)
WO (1) WO2009076220A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041377A1 (en) * 2009-09-29 2011-04-07 Eyegate Pharmaceuticals, Inc. Ocular iontophoresis of charged micelles containing bioactive agents
JP2013506006A (ja) * 2009-09-29 2013-02-21 アイゲート・ファーマシューティカルズ・インコーポレイテッド 正に帯電したポリ（ｄ，ｌ−ラクチド−コ−グリコリド）ナノ粒子及びその製造方法
CN103458879A (zh) * 2011-03-25 2013-12-18 西莱克塔生物科技公司 渗透性介导释放型合成纳米载体
EP4190395A4 (en) 2020-08-28 2024-02-21 Terumo Corp DRUG DELIVERY TOOL

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4301794A (en) * 1978-10-18 1981-11-24 Robert Tapper Method for iontophoretic treatment
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
US4747819A (en) * 1984-10-29 1988-05-31 Medtronic, Inc. Iontophoretic drug delivery
US4915685A (en) * 1986-03-19 1990-04-10 Petelenz Tomasz J Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange
US4752285B1 (en) * 1986-03-19 1995-08-22 Univ Utah Res Found Methods and apparatus for iontophoresis application of medicaments
US4979938A (en) * 1989-05-11 1990-12-25 Iomed, Inc. Method of iontophoretically treating acne, furuncles and like skin disorders
US5374245A (en) * 1990-01-10 1994-12-20 Mahurkar; Sakharam D. Reinforced multiple-lumen catheter and apparatus and method for making the same
US6139537A (en) * 1990-11-01 2000-10-31 Tapper; Robert Iontophoretic treatment system
US5252022A (en) * 1991-10-30 1993-10-12 Deere & Company Quick attachment assembly for loader implements
EP0783343A4 (en) * 1994-08-22 1999-02-03 Iomed Inc DEVICE FOR ADMINISTRATING MEDICINES WITH A HYDRATING AGENT
US5498235A (en) * 1994-09-30 1996-03-12 Becton Dickinson And Company Iontophoresis assembly including patch/controller attachment
AUPM982694A0 (en) * 1994-12-02 1995-01-05 University Of Queensland, The Iontophoresis method and apparatus
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US6018679A (en) * 1997-01-29 2000-01-25 Novartis Finance Corp. Iontophoretic transdermal delivery and control of adverse side-effects
FR2773071B1 (fr) * 1997-12-30 2001-01-05 Oreal Agent reducteur a plusieurs composants et procede de deformation permanente des cheveux le mettant en oeuvre
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6579276B2 (en) * 2001-01-22 2003-06-17 Iomed, Inc. Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (VEGF) using the same
EP1832603B1 (de) * 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
WO2006072887A1 (en) * 2005-01-05 2006-07-13 Eyegate Pharma Sa Ocular iontophoresis device for delivering sirna and aptamers
WO2007001484A2 (en) * 2005-06-20 2007-01-04 Playtex Products, Inc. Non-irritating compositions
JP2007089911A (ja) * 2005-09-29 2007-04-12 Transcutaneous Technologies Inc ｓｉＲＮＡの経皮導入方法
US20070299420A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Delivery of an agent using iontophoresis
US20070299386A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Delivery of an ocular agent using iontophoresis

Also Published As

Publication number Publication date
BRPI0820959A2 (pt) 2017-05-09
AU2008335346A2 (en) 2010-07-08
WO2009076220A1 (en) 2009-06-18
AU2008335346A1 (en) 2009-06-18
CN101965212A (zh) 2011-02-02
JP2011505917A (ja) 2011-03-03
IL206090A0 (en) 2010-11-30
CA2707964A1 (en) 2009-06-18
US20110038937A1 (en) 2011-02-17
EP2231264A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
MX2010009157A (es) Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
GB2471588A (en) Therapeutic peptidomimetic macrocycles
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
WO2011156286A3 (en) Stimulation therapy for bladder dysfunction
MX2011007930A (es) Conjugados de insulina cristalina.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
IL177483A0 (en) Means for transdermal administration of nicotine
HK1145803A1 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
EP2600834A4 (en) COLLAGEN IMPLANTS FOR THE SUSTAINABLE DELIVERY OF MEDICAMENTS
EP3583218A4 (en) TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
IN2014DN09669A (es)
WO2009023311A9 (en) Transcutaneous delivery of therapeutic agents
EP2782631A4 (en) IMPLANTABLE APPARATUS FOR USE IN THE ADMINISTRATION OF A SOLID-LIQUID MEDICAMENT, ASSOCIATED FORMULATIONS AND METHODS OF USE
ATE483716T1 (de) Lösungsmittelfreies amorphes rapamycin
EP2475358A4 (en) COMPOSITION WITH ANIONIC CORE FOR THE RELEASE OF THERAPEUTICS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2011146699A3 (en) Nanochanneled device and related methods
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
MX336812B (es) Sistema de suministro de farmaco iontoforetico co - empacado auto - contenido activado por el usuario.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
SE0701244L (sv) Distans för implantat
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
MX2010006019A (es) Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.
WO2009149205A3 (en) Cell lines that secrete soluble vegf receptors and uses thereof

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EYEGATE PHARMACEUTICALS, INC.

FA Abandonment or withdrawal